High-risk patients get conflicting messages from radiation oncologists and urologists after first-line surgical treatment

In spite of data suggesting that brachy boost has better outcomes for high-risk patients, it is being utilized less often and surgery is being utilized more often. … READ MORE …

Testosterone replacement therapy and prostate cancer risk

A new article in the Journal of Clinical Oncology has further undermined the long-held belief that there was an inherently increased risk for prostate cancer among men who received treatment with testosterone replacement therapy (TRT) for low testosterone levels. … READ MORE …

Vessel-sparing IMRT spares erectile function

While either nerve-sparing surgery or radiation can cause erectile dysfunction, the probability for that for any given patient is always worse after surgery. The recent ProtecT randomized clinical trial removed any doubt of that, if there ever really was any. … READ MORE …

A pathological “take” on the potential role of focal therapy

Various forms of focal therapy are now being used by some physicians to treat selected patients with well-identified, usually relatively small, “dominant” or “index” tumors that are confined to highly defined areas of the prostate. … READ MORE …

Data from the first really large trial of CAR-T in treatment of lymphoma

As yet, there has been no serious clinical exploration of whether the new types of CAR-T treatment can be applied to patients with either prostate cancer or any other form of solid tumor. … READ MORE …

Conference call/webinar on bipolar androgen therapy (BAT)

For those who are interested, the Answer Cancer Foundation has let us know that they will be holding an educational conference call/webinar at 8:00 pm Eastern (5:00 pm Pacific) today on the subject of bipolar androgen therapy in the treatment of advanced prostate cancer. … READ MORE …

SpaceOAR hydrogel — is the difference worthwhile?

SpaceOAR hydrogel is spacer injected between the rectum and the prostate that increases their separation (in men being treated with external beam radiation therapy). This allows less radiation targeted at the prostate to hit the rectum. The research group published an interim 15-month report in 2015, and now Hamstra et al. have published their final report based on 3 years of follow-up. … READ MORE …